About Pre-mRNA-splicing factor RBM22
Pre-mRNA-splicing factor RBM22 (RBM22) is a protein
from Homo sapiens identified by UniProt accession
Q9NW64, 420 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Pre-mRNA-splicing factor RBM22 |
| UniProt accession | Q9NW64 |
| Gene | RBM22 |
| Organism | Homo sapiens |
| Length | 420 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (110)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- glioblastoma · score 0.07
- Syndactyly type 2 · score 0.06
- syndactyly type 4 · score 0.06
- Split hand-split foot malformation · score 0.05
- syndactyly type 5 · score 0.05
- mesoaxial synostotic syndactyly with phalangeal reduction · score 0.05
- synpolydactyly type 1 · score 0.05
- syndactyly type 1 · score 0.05
- polydactyly of a triphalangeal thumb · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NW64-F1 | alphafold | PREDICTED | 76.10 | — |
Amino-acid sequence (420 residues)
MATSLGSNTY NRQNWEDADF PILCQTCLGE NPYIRMTKEK YGKECKICAR PFTVFRWCPG VRMRFKKTEV CQTCSKLKNV CQTCLLDLEY GLPIQVRDAG LSFKDDMPKS DVNKEYYTQN MEREISNSDG TRPVGMLGKA TSTSDMLLKL ARTTPYYKRN RPHICSFWVK GECKRGEECP YRHEKPTDPD DPLADQNIKD RYYGINDPVA DKLLKRASTM PRLDPPEDKT ITTLYVGGLG DTITETDLRN HFYQFGEIRT ITVVQRQQCA FIQFATRQAA EVAAEKSFNK LIVNGRRLNV KWGRSQAARG KEKEKDGTTD SGIKLEPVPG LPGALPPPPA AEEEASANYF NLPPSGPPAV VNIALPPPPG IAPPPPPGFG PHMFHPMGPP PPFMRAPGPI HYPSQDPQRM GAHAGKHSSP
Explore Pre-mRNA-splicing factor RBM22 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets